Yonsei University Clinical Investigator Discusses Results of Opdivo Trial to Address Esophageal Cancer

Esophageal patients have had little option other than chemotherapy for a long time.  Could immunotherapies change that? First Keytruda was approved to treat PD-L1 positive advanced squamous cell esophageal cancer and recently Opdivo (nivolumab) evidenced therapeutic...

Pin It on Pinterest